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A B S T R A C T
Background: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative in-
dividuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for
PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically;
crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been
associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men
(GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported
chemsex events affected self-reported daily PrEP adherence among PROUD study participants.
Methods: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual
health clinics, assessing effectiveness of TruvadaⓇ-PrEP among 544 HIV-negative GBM. The study reported an
86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up
visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits.
Univariable and multivariable regression analyses were performed to test for associations between chemsex and
reporting less than seven out of seven intended doses(< 7/7ID) in the 7 days before and/or after last condomless
anal intercourse(CAI).
Results: 1479 follow-up visit forms and 2260 monthly adherence forms from 388 participants were included in
the analyses, with 38.5% visit forms reporting chemsex since last visit and 29.9% follow-up periods re-
porting< 7/7ID. No statistically significant associations were observed between reporting<7/7ID and
chemsex (aOR=1.29 [95% CI 0.90–1.87], p=0.168). Statistically significant associations were seen between
reporting< 7/7ID and participants perceiving that they would miss PrEP doses during the trial, Asian ethnicity,
and reporting unemployment at baseline.
Conclusions: These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM
engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV
transmission risk.
Introduction
In November 2018, Public Health England (PHE) reported sig-
nificant progress towards ending the HIV epidemic; the UNAIDS
90:90:90 targets had been met for England in 2017, and a 17% decline
in new UK HIV diagnoses compared to 2016 (from 5,280 to 4,363) had
been observed in both gay, bisexual and other men who have sex with
men (GBM) and heterosexual groups (Nash S et al., 2018). The stepwise
implementation of combination HIV prevention; condom provision,
scale up of frequent HIV testing and prompt antiretroviral therapy
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T
(ART) after diagnoses, and pre-exposure prophylaxis (PrEP), has been
identified as the primary drivers for the drop in HIV incidence in GBM.
Despite these gains, just over half (53%) of all new HIV diagnoses in
England in 2017 were among GBM, demonstrating that this group are
disproportionately at risk of acquiring HIV (Nash S et al., 2018).
Pre-exposure prophylaxis (PrEP) is an innovative HIV prevention
strategy for individuals at risk for HIV acquisition, such as GBM enga-
ging in condomless anal intercourse (CAI) (McCormack, Fidler et al.,
2016). Although PrEP is not yet routinely commissioned in England, it
is available through the PrEP Impact Trial (Nash S et al., 2018;
NHS England, 2017) and can be purchased online and by private pre-
scription. PrEP's efficacy in reducing HIV incidence in GBM and het-
erosexuals has been documented widely (Baeten et al., 2012;
Huang et al., 2018; (McCormack et al., 2016; Molina et al., 2015;
Okwundu, Uthman & Okoromah, 2012) and in trials such as the PROUD
study, an open-label, randomized controlled trial of 544 HIV-negative
GBM, the reduction in HIV risk from daily PrEP was 86% (McCormack
et al., 2016). Optimal adherence is critical to PrEP's efficacy in HIV
prevention, in order to achieve protective drug levels in the blood
(Desai, Field, Grant & McCormack, 2017; Fonner et al., 2016;
Huang et al., 2018; Spinner et al., 2016) and consequently, studies
reporting limited PrEP efficacy have detected low or no therapeutic
drug levels, indicating poor adherence (Corneli et al., 2014; Grant et al.,
2014; Haberer et al., 2013; Marrazzo et al., 2015; Van Damme et al.,
2012).
Chemsex refers to the use of psychoactive drugs within a sexual
context to enhance and facilitate sexual experiences (Public Health
England, 2015). The international chemsex definition varies, but within
the UK typically involves the use of one or more of the three drugs;
crystal methamphetamine, gamma-hydroxybutyrate [GHB] and me-
phedrone. (Bourne, Reid, Hickson, Torres-Rueda & Weatherburn, 2015;
Edmundson et al., 2018; Public Health England, 2015). Chemsex has
been increasingly reported among UK GBM in recent years
(Macfarlane, 2016; Ottaway, Finnerty, Buckingham & Richardson,
2017; Sewell et al., 2018; Tomkins, George & Kliner, 2019) but pre-
valence estimates vary considerably due to lack of a standardised de-
finition of chemsex and lack of prevalence measurements among re-
presentative, national samples of GBM. Furthermore, much of the
available literature on chemsex only uses reporting of drugs associated
with chemsex as a proxy for chemsex behaviour (i.e. intentional sex
under the influence of the psychoactive drugs crystal methampheta-
mine, gamma-hydroxybutyrate [GHB], mephedrone) and does not as-
sess event-level data. (Edmundson et al., 2018; Sewell et al., 2018).
Chemsex drug use has been associated with a number of harms in-
cluding; sexual and other behaviours carrying HIV and hepatitis C risk
(such as CAI, group sex and multiple partners, fisting and injecting)
(Bourne et al., 2015; Daskalopoulou et al., 2017; Glynn et al., 2018;
Hegazi et al., 2017; Maxwell, Shahmanesh & Gafos, 2019;
Ristuccia, LoSchiavo, Halkitis & Kapadia, 2018; Tomkins et al., 2019),
HIV diagnosis (Halkitis, Levy, Moreira & Ferrusi, 2014;
Kenyon, Wouters, Platteau, Buyze & Florence, 2018; Pakianathan et al.,
2018; White et al., 2019) and suboptimal adherence to ART among
people living with HIV (Daskalopoulou et al., 2014; Perera, Bourne &
Thomas, 2017; Stuart, 2013). The evidence on chemsex impacting ART
adherence includes a systematic review published in 2017, reporting
chemsex drug users as having 23% higher odds of ART non-adherence
than non-chemsex drug users (OR 1.23, 95%CI 1.10–1.38, I2 0%,
p=0.372) (Perera et al., 2017). However as described earlier, the
majority of studies on chemsex associated harms use chemsex drug use
as a proxy, therefore attributing these harms to chemsex behaviours
directly is problematic.
Evidence assessing the effect of chemsex behaviour and chemsex
drug use on individuals’ PrEP adherence is limited and conflicting. One
qualitative study among American PrEP-taking GBM reported associa-
tions between methamphetamine use and poor PrEP adherence, often in
the context of group sex (Storholm, Volk, Marcus, Silverberg & Satre,
2017). Another American GBM study found similar associations with
instances of “club drug” use (including GHB and methamphetamine)
being correlated with missed PrEP doses on the same day (Grov,
Rendina, John, & Parsons, 2018). Conversely, the same research also
suggested that on average “club drug” users were no more likely to miss
PrEP doses than non “club drugs” users (Grov, Rendina, John, &
Parsons, 2018), and in another study among American GBM, me-
thamphetamine use was shown not to be associated with decreased
PrEP adherence (Hoenigl, Morgan, et al., 2019; Hoenigl, Morgan, et al.,
2019). Interestingly, in an IPERGAY trial substudy, GBM reporting
chemsex were more likely to report correct PrEP use during their most
recent sexual encounter, which authors have explained by their addi-
tional finding that participants reporting chemsex also reported having
a higher risk perception (Roux et al., 2018).
To our knowledge, there is currently no evidence assessing the
impact of chemsex behaviours on PrEP adherence among GBM in
England. This study explores the effect of reported chemsex episodes on
daily PrEP adherence among PROUD study participants, to assess
whether PrEP is likely to be an effective HIV prevention tool in periods
around these high-risk events.
Methods
The PROUD study was an open-label, wait-listed, randomized con-
trolled trial that was conducted in thirteen sexual health clinics in
England, examining the real-world effectiveness of daily oral TruvadaⓇ
as HIV PrEP. The study recruited 544 HIV-negative GBM between
November 2012 and April 2014 who reported CAI in the previous 90
days and who considered they were likely to have CAI in the next 90
days. Participants were randomly assigned daily TruvadaⓇ either at
study enrolment or after 12 months. Participants were followed up
approximately quarterly with HIV/STI screening. In October 2014, in-
terim analyses showed a large number of HIV infections in the deferred
arm and evidence of PrEP being highly protective in the immediate
arm, prompting a study design amendment whereby the X deferral arm
participants still in the first 12 months of follow-up were given access to
PrEP (McCormack, Dunn et al., 2016; . PROUD study design, baseline
participant characteristics and results are described elsewhere
(Dolling et al., 2016; Gafos, Brodnicki, et al., 2017;
McCormack, Dunn et al., 2016;
From March 2015, participants were asked at each follow-up visit
whether they had engaged in chemsex since last visit, on clinician-
completed questionnaires. Specifically, these questionnaires asked,
“Has the participant engaged in any of the following since their last
visit: crystal meth, GHB/GBL or mephedrone immediately prior to, or
during, sex (“chemsex”)”. Visit questionnaires answering yes to this
question were used to define periods of chemsex engagement within the
90 days prior to follow-up visit dates (as follow-up visits were supposed
to occur quarterly). Visit questionnaires were excluded from the ana-
lyses if they were from participants who were not currently taking PrEP
or if the question on chemsex was not answered.
Participants were asked to complete monthly self-reported PrEP
adherence questionnaires for the last month only; online, or on paper at
follow-up visits. These adherence questionnaires asked participants
how many days they missed PrEP tablets in the seven days before and
seven days after last CAI (provided this had occurred in the preceding
30 days) and were used to assess adherence execution (Vrijens et al.,
2012). Adherence questionnaires were eligible for our analyses if the
completion date was within 90 days prior to the date on the visit
questionnaire completion dates (and hence could be linked) and if the
questions on missed PrEP were answered. We created a binary ad-
herence outcome measure for participants reporting; taking all seven
out of seven intended doses (7/7ID) in the seven days before and after
last CAI, and participants reporting less than seven out of seven in-
tended doses (< 7/7ID) in the 7 days before and/or after last CAI. It
was not possible to conduct a robust analysis with an adherence
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outcome for participants reporting missing ≥4 PrEP tablets in the 7
days before and/or after last CAI, as the sample was too small.
The adherence questionnaires were aggregated to calculate an
overall PrEP adherence measure for each follow-up period. If partici-
pants reported 7/7ID in all monthly adherence questionnaires within
the visit follow-up period, then the entire follow-up period would be
defined as reporting 7/7ID. If participants reported<7/7ID any
monthly adherence questionnaire within the follow-up period this
would denote the follow-up period as reporting< 7/7ID. Monthly and
follow-up period adherence classifications are described in Table 1.
Statistical analysis
Comparative analyses using univariable logistic regression were
performed to assess associations between the outcome and exposure of
interest (< 7/7ID within a follow-up period and chemsex reporting)
and other covariates collected on baseline questionnaires at enrolment
and visit questionnaires at each follow-up visit (demographics, lifestyle,
sexual behaviour etc.). A forward stepwise approach was used for the
multivariable model with chemsex, with variables entered where sig-
nificant at p<0.1. Since participants could contribute to the analysis
multiple times, robust variance was used for logistic regression analyses
to account for clustering. Data were analysed using STATA 15.1.
Results
Our sample consisted of 1,479 visit questionnaires, 2,260 monthly
adherence questionnaires and 388 baseline enrolment questionnaires
derived from 388 participants, between 3rd December 2014 and 28th
October 2016. The median number of follow-up visit questionnaires per
participant over the study period was four (interquartile range [IQR]:
2–5), and the median number of adherence forms per participant was
five (IQR: 3–7). The median number of adherence forms within a visit
form period was 1 (IQR: 1–2).
Baseline characteristics
Descriptive analyses of participants from baseline questionnaires
are detailed in Table 2 and were highly similar to baseline character-
istics reported for the total PROUD study population (Dolling et al.,
2016). Among the 388 participants within this study, median age was
36 years (IQR 30–43), 82% reported being of white ethnicity, and
60.6% were UK born. Almost all participants described their gender as
male (99%; 384), and their sexuality as gay/homosexual (95.1%; 369).
Among the participants, 43.3% reported currently being in a relation-
ship, 63.4% reported completing a university degree or higher, and
73.2% were in full-time employment.
Almost three quarters of participants (73.7%; 286) reported having
used any recreational drugs in the three months prior to enrolment.
Four in ten participants (43%; 167) reporting using one or more of the
three chemsex-associated drugs, with a smaller proportion (12.9%; 50)
reporting having used all three chemsex-associated drugs. 13.7%
reporting drinking alcohol daily or nearly every day.
Participant prep adherence and chemsex reporting during follow-up
Nearly a quarter (23.3%; 527/2,260) of all adherence forms within
our sample reported< 7/7ID, with the majority (72.9%, 384/527) of
these only reporting missing less than three intended doses in the week
before and after last CAI. Chemsex and PrEP adherence reporting by
participants at any time during their study period are described in
Fig. 1. Just over half (52.8%, 205) of the participants ever reported
engaging in chemsex on a follow-up visit questionnaire and just over
half (53.1%, 206) ever had a follow-up period reporting<7/7ID. Most
participants (85.8%, 333) had one or more follow-up period reporting
7/7ID.
Follow-up period characteristics
Descriptive clinical, lifestyle and sexual behaviour characteristics
from the 1,479 visit questionnaires are described in Table 3. Chemsex
was reported on 38.5% visit questionnaires, 47.1% visit questionnaires
reported group sex, 24% reported using sex toys and 13.9% reported
fisting, since last visit. The median number of CAI partners in the 30
days prior to visit was 3 (IQR: 1–7). Only 8.8% of visit questionnaires
reported an episode of injecting drug use and 20.1% reported powder
cocaine use.
Factors associated with reporting less than 7 of 7 intended doses (≤7/7ID)
within a follow-up period (Table 4)
The univariable analyses demonstrated no statistically significant
(p<0.05) association between chemsex engagement reported on
follow-up visit questionnaires and reporting<7/7ID within linked
follow-up periods (OR=1.29 [95% CI: 0.92–1.79], p=0.137). Just
over a third (33.2%) of follow-up periods linked to a visit questionnaire
reporting chemsex since last visit reported<7/7ID and 27.8% follow-
up periods linked to visit questionnaires not reporting chemsex re-
ported<7/7ID.
Ethnicity, employment status and participants’ baseline perception
of their adherence ability were entered into the multivariable model
assessing chemsex and reporting<7/7ID within a follow-up period, as
these were significant at p<0.1 during the selection process. The as-
sociation between chemsex and reporting<7/7ID remained statisti-
cally non-significant at p<0.05 (aOR=1.29 [95% CI: 0.90–1.87],
p=0.168). Within the multivariable analyses, visit questionnaires from
participants perceiving at baseline they may encounter adherence dif-
ficulties were significantly associated with reporting< 7/7ID at
p<0.05 (aOR=1.88 [95% CI: 1.28–2.75], p=0.001), as was re-
porting unemployment (aOR=2.31 [95% CI: 1.06–5.04], p=0.036)
and Asian ethnicity (aOR=3.12 [95% CI: 1.20–8.21], p=0.020).
Although in the univariable analyses, visit questionnaires from
participants in full-time education and aged 18–35 at baseline were
significantly associated with reporting<7/7ID within a follow-up
Table 1
Monthly and follow-up period PrEP adherence classifications.
Monthly PrEP adherence
Seven out of seven intended doses (7/7ID) Less than seven out of seven intended doses (< 7/7ID)
Participant reports missing 0 PrEP tablets in both 7 days before and 7 days after last CAI
on monthly adherence form
Participant reports missing ≥1 PrEP tablet(s) in 7 days before and/or 7 days after last
CAI on monthly adherence form
Follow-up period PrEP adherence
Seven out of seven intended doses (7/7ID) within a follow-up period Less than seven out of seven intended doses (< 7/7ID) within a follow-up period
All monthly adherence forms within follow-up period between visits report taking
seven out of seven intended doses in the 7 days before and 7 days after last CAI
≥1 monthly adherence form(s) within follow-up period between visits reports less than
seven out of seven intended doses in the 7 days before and/or 7 days after last CAI
C. O'Halloran, et al. International Journal of Drug Policy 74 (2019) 246–254
248
period, these variables were not retained in the final multivariable
model as they were no longer significant at p<0.1.
Discussion
This analysis has shown no statistically significant association be-
tween reporting less than seven out of seven intended PrEP doses (< 7/
7ID) and reporting chemsex event periods among GBM. Although the
direction of association is similar to that observed in the meta-analysis
by Perera et al. (2017) between chemsex and ART non-adherence, their
work focussed on reported use of drugs associated with chemsex only
(i.e. not chemsex behaviour) and was assessed at the individual level.
Our study assessed event-level data and measured specific reporting of
chemsex behaviour by PROUD participants. Although ART and PrEP are
both regular HIV-related medications used by GBM, they are taken for
different purposes, the former to treat existing HIV infection, and the
latter to prevent HIV acquisition. Therefore, motivations to adhere
optimally will likely vary.
There is a growing amount of evidence suggesting that not all
chemsex episodes or behaviours are inherently harmful, and that many
GBM can successfully integrate sexualised drug use into their lives,
whilst still being in control of their actions (Bourne, Reid, Hickson,
Rueda & Weatherburn, 2014). Some sources report chemsex users as
having relatively controlled drug use and maintaining safe sex strate-
gies whilst under the influence of chemsex drugs (Graf, Dichtl, Deimel,
Sander & Stover, 2018), or completely compartmentalising chemsex
from the rest of their lives (Ahmed et al., 2016), suggesting that daily
PrEP adherence around chemsex events can be achievable. A follow-up
study of the TAPIR PrEP trial also found “less problematic” substance
use to be a significant predictor of adequate adherence (Hoenigl,
Hassan et al., 2019) and a recent study among Australian GBM has
reported increased concurrent use of methamphetamines, Viagra and
TruvadaⓇ-PrEP, demonstrating how PrEP can be added alongside
chemsex drug use to mitigate against HIV risk (Hammoud et al., 2018).
It is also possible that GBM engaging in chemsex use tailored PrEP
adherence strategies around periods of chemsex to ensure doses are not
missed. Adapted PrEP adherence strategies documented among GBM
engaging in sexualised drug use include habitually taking PrEP tablets
at the start of the day and taking with other medications or when
preparing for sex (Closson, Mitty, Malone, Mayer & Mimiaga, 2018). A
study among thirty American GBM using PrEP and reporting illicit drug
use found that although all individuals found that methamphetamine
use negatively impacted PrEP adherence ability, many used innovative
ways of remembering daily doses; 60% reported using reminder devices
or memory techniques and 6.7% reported borrowing from peers and
partners (Storholm et al., 2017).
Significantly higher odds of reporting<7/7ID within a follow-up
period were observed from participants reporting at baseline that they
may forget PrEP doses, compared to those perceiving they would find
daily dosing easy. If PrEP becomes routinely available in England, it
would be beneficial for clinicians to ascertain patients’ perception of
their ability to adhere to PrEP during initial consultations, and provide
adherence support where this is required. Compared to those of white
ethnicity and those in full-time employment, follow-up periods from
individuals of Asian ethnicity and those unemployed at baseline, also
had significantly higher odds of reporting<7/7ID respectively, high-
lighting additional population groups that may benefit from adherence
monitoring and support.
Strengths and limitations
This study benefitted from PROUD's large sample size and extensive
collection of demographic, sexual behaviour and lifestyle data, allowing
us to examine and adjust for multiple potential correlates and con-
founders for PrEP adherence. Our baseline data was also highly re-
presentative of the entire PROUD study population (Dolling et al.,
2016), indicating that questionnaire exclusion criteria did not skew
sample characteristics. As PROUD was delivered through thirteen
sexual health clinics in six major English cities, this allows the results to
be generalizable to urban populations of GBM at risk of HIV in England.
These results may not, however, be generalizable to “low-risk” and non-
urban GBM.
A major strength for this study was being able to use data that ex-
plicitly asked participants whether they engaged in chemsex using a
specific chemsex definition, instead of using chemsex drug use as a
proxy for the chemsex behaviour. Of the of 415 PROUD participants
Table 2
Participant sample characteristics at baseline from linked enrolment ques-
tionnaires (N=388 participants).
Demographics n (%)
Gender
Male 384 (99)
Transgender 0 (0)
Sexuality
Gay/homosexual 369 (95.1)
Straight/bisexual/other 15 (3.9)
Ethnicity
White 318 (82)
Black 13 (3.4)
Asian 18 (4.6)
Other 36 (9.3)
Born in the UK
No 151 (38.9)
Yes 235 (60.6)
Age (years)
18–25 40 (10.3)
26–35 145 (37.4)
36–45 119 (30.7)
>45 84 (21.7)
Maximum education level
University degree or higher 246 (63.4)
A levels / equivalent 61 (15.7)
GCSEs / equivalent 38 (9.8)
Vocational training/other qualifications 23 (5.9)
Still in full-time education 10 (2.6)
Finished education with no qualifications 9 (2.3)
Employment status
Employed/self-employed full-time 284 (73.2)
Employed/self-employed part-time 38 (9.8)
Unemployed 24 (6.2)
Student 16 (4.1)
Retired 16 (4.1)
Other 7 (1.8)
Relationship status
In relationship, living with partner 113 (29.1)
In relationship, not living with partner 55 (14.2)
Not currently in an ongoing relationship 218 (56.2)
Lifestyle
Recreational drug use in past 3 months
No 92 (23.7)
Yes 286 (73.7)
Alcohol drinking frequency
Never/Once 40 (10.3)
2 or 3 times a month 80 (20.6)
Once or twice a week 128 (33)
3 or 4 times a week 75 (19.3)
Nearly every day/Daily 53 (13.7)
Units of alcohol drank on a typical drinking day
0–4 163 (42)
5–9 117 (30.2)
10+ 60 (15.5)
Perception of adherence ability throughout the trial
Find easy to remember to take drug daily 250 (64.4)
Might forget to take doses, will find daily dosing difficult 122 (31.4)
Number of baseline enrolment questionnaires with missing data for gender (4);
sexuality (4); ethnicity (3); born in the UK (2); education (1) employment (3)
relationship status (2); recreational drug use (5); alcohol drinking frequency
(12) alcohol units (48) perception of adherence (16)
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who completed acceptability questionnaires on the PROUD study de-
sign, 88% also reported feeling they could disclose sexual activity
honestly, strengthening the validity of our exposure measurement
(Gafos, Brodnicki, et al., 2017; . The longitudinal nature of PROUD
meant multiple adherence data could be linked to multiple reported
chemsex episodes over the study period; this would not have been
possible if the analyses had been performed per participant, using an
overall adherence measure for total individual follow-up time, and
categorizing participants as chemsex and non-chemsex users. As both
adherence and sexual behaviour may not be consistent for a participant
throughout their trial follow-up, this was important to investigate, as
much of the chemsex literature lacks event-level data
(Edmundson et al., 2018). Visit questionnaires only asked participants
one question about whether they engaged in chemsex, defined as using
crystal methamphetamine, GHB/GBL or mephedrone immediately prior
to, or during, sex. As the questionnaires did not ask participants to
specify which of these three chemsex drugs were used, we were unable
to assess associations between adherence and specific chemsex drug
combinations.
Although some trials have observed self-reporting to provoke
overestimations of adherence, it has also been demonstrated to be as
accurate as refill and biological PrEP adherence measures in other trials
(Amico et al., 2016; Lal et al., 2017; Montgomery et al., 2016; Vaccher
et al., 2018) and self-reporting would have reduced social desirability
bias compared to interviewing. Measuring adherence through missed
doses before and after last condomless sex also meant adherence esti-
mates were captured around critical risk periods for PrEP to be needed,
however chemsex engagement itself could affect social desirability and
recall bias when self-reporting adherence and recalling adherence, re-
spectively.
An important drawback of this study is that reported chemsex
events cannot be linked to the exact timeframe within the follow-up
period where participants recorded missed pills. Further work is needed
which asks GBM about PrEP adherence specifically during chemsex
events. Our adherence classifications in Table 1 also meant that any
single monthly adherence questionnaires reporting<7/7ID would
denote an entire follow-up period as reporting< 7/7ID. This would,
however, most likely overestimate any negative impact of chemsex on
adherence, which is contradictory to our findings. During data collec-
tion, we found that the majority of follow-up periods only had one
linked monthly adherence questionnaire. As follow-up visits were
supposed to be quarterly, this could mean there were months within a
follow-up period where PrEP adherence was not captured on an ad-
herence form. We are also aware that although follow-up visits were
meant to be quarterly, in practise they did not always occur every 90
days, which was our cut-off for linking prior adherence forms to a
follow-up visit date. Participants returning for follow-up visits were also
almost exclusively doing so to obtain PrEP, hence participants who
were adhering well to their PrEP may have been more likely to attend
Fig. 1. Participant follow-up period PrEP adherence and chemsex reporting throughout trial follow-up (N=388).
Table 3
Visit questionnaire sample characteristics (N=1479 visit questionnaires).
Clinical n (%)
Illness preventing daily activities since last follow-up visit
No 1359 (91.9)
Yes 120 (8.1)
Side effects to Truvada in last 30 days
No 1433 (96.9)
Yes 38 (2.6)
Lifestyle
Injected drugs since last follow-up visit
No 1348 (91.1)
Yes 130 (8.8)
Snorted cocaine since last follow-up visit
No 1182 (79.9)
Yes 297 (20.1)
Sexual behaviour
Number of condomless anal sex partners since last follow-up visit
0 77 (5.2)
1 362 (24.5)
2–5 606 (41)
>6 433 (29.3)
Engaged in chemsex since last follow-up visit
No 909 (61.5)
Yes 570 (38.5)
Engaged in group sex since last follow-up visit
No 783 (52.9)
Yes 696 (47.1)
Used sex toys since last follow-up visit
No 1124 (76)
Yes 355 (24)
Engaged in fisting since last follow-up visit
No 1273 (86.1)
Yes 205 (13.9)
Follow-up period prep adherence
<7/7ID reported within last 90-day period
No 1037 (70.1)
Yes 442 (29.9)
Number of follow-up visit questionnaires with missing data for side effects (8);
injected drugs(1); number of condomless anal sex partners (1); fisting (1)
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Table 4
Factors associated with reporting less than 7 of 7 intended doses (< 7/7ID) in a follow-up period, from univariable and multivariable logistic regressions (N=1479
follow-up visit questionnaires, N=388 participants)a.
Reporting <7/7ID in a follow-up period
Univariable Multivariable
Totalc nd (%)e Unadjusted OR (95%
CI)
P Adjusted OR (95%
CI)
P
Baseline enrolment questionnaire variables - DEMOGRAPHICS
Gender Male 1465 442 (30.17%)
Transgender - (0.00%)
Sexuality Gay/homosexual 1397 416 (29.78%) 1 0.851
Straight/Bisexual/Other 66 21 (31.82%) 1.10 (0.41–2.99)
Ethnicity White 1196 336 (28.09%) 1 1
Black 51 22 (43.14%) 1.94 (0.78 –4.80) 0.151 1.78 (0.71 – 4.49) 0.222
Asian 69 30 (43.48%) 1.97 (0.84 –4.63) 0.120 3.12 (1.20 – 8.21) 0.020b
Other 151 50 (33.11%) 1.27 (0.76 –2.12) 0.368 1.13 (0.64 – 1.97) 0.678
Born in the UK No 569 171 (30.05%) 1 0.977
Yes 905 271 (29.94%) 0.99 (0.70 –1.42)
Age (years)f 18–25 148 62 (41.89%) 2.73 (1.48–5.04) 0.001b
26–35 532 181 (34.02%) 1.95 (1.21 –3.16) 0.006b
36–45 435 123 (28.28%) 1.49 (0.90 –2,47) 0.118
>45 364 76 (20.88%) 1
Maximum education levelf University degree or higher 965 282 (29.22%) 1
A levels / equivalent 201 65 (32.34%) 1.16 (0.70 –1.91) 0.565
GCSEs / equivalent 149 36 (24.16%) 0.77 (0.40–1.49) 0.441
Vocational training/other qualifications 92 32 (34.78%) 1.29 (0.67–2.49) 0.444
Still in full-time education 39 20 (51.28%) 2.55 (1.05–6.21) 0.039b
Finished education with no
qualifications
29 7 (24.14%) 0.77 (0.24–2.44) 0.658
Employment status Employed/self-employed full time 1050 298 (28.38%) 1 1
Employed/self-employed part time 134 46 (34.33%) 1.32 (0.77–2.27) 0.318 1.48 (0.81–2.70) 0.203
Student 107 43 (40.19%) 1.70 (0.88 –3.29) 0.118 1.57 (0.75 –3.30) 0.233
Unemployed 77 30 (38.96%) 1.61 (0.72–3.62) 0.248 2.31 (1.06–5.04) 0.036b
Retired 70 15 (21.43%) 0.69 (0.24–1.99) 0.491 0.53 (0.12 –2.35) 0.403
Other 30 10 (33.33%) 1.26 (0.45–3.50) 0.655 0.53 (0.23–1.22) 0.138
Relationship status In relationship, living with partner 429 110 (25.64%) 1
In relationship, not living with partner 192 55 (28.65%) 1.16 (0.64 –2.13) 0.621
Not currently in an ongoing relationship 851 277 (32.55%) 1.40 (0.92–2.12) 0.114
Baseline enrolment questionnaire variables - Lifestyle
Recreational drug use in past 3 months No 371 114 (30.73%) 1 0.718
Yes 1071 312 (29.13%) 0.93 (0.61–1.40)
Alcohol drinking frequency Never/Once 169 46 (27.22%)
2 or 3 times a month 312 103 (33.01%) 1.32 (0.68 –2.55) 0.412
Once or twice a week 483 133 (27.54%) 1.02 (0.53 –1.95) 0.962
3 or 4 times a week 286 96 (33.57%) 1.35 (0.67 –2.71) 0.396
Nearly every day/Daily 190 48 (25.26%) 0.90 (0.43 –1.90) 0.790
Units of alcohol drank on a typical
drinking day
0–4 642 202 (31.46%) 1
5–9 442 129 (29.19%) 0.90 (0.60 –1.34) 0.597
≥10 212 58 (27.36%) 0.82 (0.50–1.34) 0.431
Perception of adherence ability
throughout the trial
Will find easy to remember to take drug
daily
966 249 (25.78%) 1 0.002b 1 0.001b
Might forget to take doses/ will find
daily dosing difficult
462 175 (37.88%) 1.76 (1.23–2.51) 1.88 (1.28 –2.75)
Follow-up questionnaire variables - Clinical
Illness preventing daily activities since last
visit
No 1359 398 (29.29%) 1 0.116
Yes 120 44 (36.67%) 1.40 (0.92 –2.12)
Side effects to Truvada in last 30 days No 1433 426 (29.73%) 1 0.599
Yes 38 10 (26.32%) 0.84 (0.45 –1.59)
Follow-up questionnaire variables - Lifestyle
Injected drugs since last visit No 1348 399 (29.60%) 1 0.684
Yes 130 42 (32.31%) 1.14 (0.62 –2.09)
Snorted cocaine since last visit No 1182 343 (29.02%) 1 0.25
Yes 297 99 (33.33%) 1.22 (0.87–1.72)
Follow-up questionnaire variables – Sexual behaviour
Number of condomless anal sex partners
since last visit
0 77 20 (25.97%) 1
1 362 116 (32.04%) 1.34 (0.74 –2.43) 0.327
2–5 606 176 (29.04%) 1.17 (0.64–2.14) 0.619
≥6 433 130 (30.02%) 1.22 (0.64 –2.32) 0.539
Chemsex engagement since last visit No 909 253 (27.83%) 1 0.137 1 0.168
Yes 570 189 (33.16%) 1.29 (0.92–1.79) 1.29 (0.90 –1.87)
Group sex since last visit No 783 249 (31.80%) 1 0.194
Yes 696 193 (27.73%) 0.82 (0.61–1.10)
(continued on next page)
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and contribute to our substudy cohort, potentially leading to an un-
derestimation of any associations with reporting<7/7ID.
Our adherence measure may seem stringent due to evidence that
taking PrEP ≥4/7 days a week is sufficient protection against HIV
acquisition during anal sex (Anderson et al., 2012; (Grant et al., 2014)).
The same analysis was repeated with missing ≥4/7 days of intended
PrEP doses around last CAI as the adherence outcome measure, and no
significant association with chemsex was found, however the sample
size was too small to provide robust estimates due to the low proportion
of follow-up periods (95/1479) that qualified for inclusion.
Chemsex reporting was clinician-completed at follow-up visits,
meaning chemsex may have been underreported due to social desir-
ability or acquiescence bias. Participants were asked about their last
CAI in the 30 days prior in order to maximise recall for the adherence
data, but participants were asked about chemsex activity since last
follow-up visit (approx. quarterly), potentially introducing recall bias.
Some participants reported difficulty in remembering sexual activity
during recall periods, and finding questionnaires laborious and the
monthly adherence questionnaires specifically hard to remember to
complete (Gafos, Brodnicki, et al., 2017; Nonetheless, 82% of partici-
pants completing acceptability questionnaires reported not minding
completing the monthly adherence forms (Gafos, Brodnicki, et al.,
2017;
As PROUD participants had regular contact with clinics and fre-
quent questionnaires reviewing adherence, the Hawthorne effect
(Wickstrom & Bendix, 2000) could have influenced the optimal ad-
herence profiles observed, through modified behaviour provoking im-
proved adherence, and not reflecting true adherence whilst not under
observation. Further insight into how chemsex users adhere to PrEP
outside a trial setting is needed. As this substudy only measured the
implementation component of adherence, it would be beneficial to
measure initiation and persistence of PrEP adherence in the context of
chemsex, as these adherence components are important in terms of risk
of HIV acquisition Gafos, White, et al., 2017; Vrijens et al., 2012). As
participants were not paying for their PrEP, their adherence may also
change if there is an individual financial cost.
Conclusion
These analyses suggest that chemsex is not a barrier to optimal PrEP
adherence among the PROUD study cohort, and that PrEP remains a
feasible and effective prevention tool among GBM in England engaging
in a sexual behaviour that is associated with HIV risk. These data
strengthen evidence of PrEP's effectiveness as a key combination pre-
vention method in the UK's progress towards ending the HIV epidemic.
Whilst regular monitoring is recommended to help chemsex users
manage their risk of chemsex associated harms, including HIV
acquisition, it would be pertinent for clinicians to risk assess ethnic
minority and unemployed individuals, or those with perceived ad-
herence difficulties during initial PrEP prescribing, to ascertain if ad-
herence support is needed.
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Reporting <7/7ID in a follow-up period
Univariable Multivariable
Totalc nd (%)e Unadjusted OR (95%
CI)
P Adjusted OR (95%
CI)
P
Used sex toys since last visit No 1124 334 (29.72%) 1 0.843
Yes 355 108 (30.42%) 1.03 (0.74–1.44)
Fisting since last visit No 1273 386 (30.32%) 1 0.434
Yes 205 55 (26.83%) 0.84 (0.55–1.29)
a Missing data from enrolment and visit questionnaires not included in logistic regression analyses.
b Association considered significant (P<0.05).
c total number of follow-up visit questionnaires reporting row variable.
d total number of follow-up visit questionnaires reporting row variable and< 7/7ID within linked 90-day follow-up period.
e Row percentages based on non-missing data.
f Not included retained in final multivariable logistic regression analyses as p-value> 0.1 in multivariable model.
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